CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Endpoints News
Original article

Lycia seeks IPO for antibody degrader work as TRexBio, Retension forge ahead

IPO/OfferingPositive
AI Analysis

Summary

Lycia Therapeutics, a protein degradation startup founded on science from Nobel laureate Carolyn Bertozzi, has filed for an initial public offering. TRexBio and Retension are also advancing their own development programs.

Importance:6/10
Sentiment:
0.50
protein degradationantibody degraderIPOCarolyn Bertozzi

Read the original article

Published by Endpoints News on October 6, 2026 8:21 AM

Read Original